Phase 4CompletedAge-related condition
Study of Efficacy and Safety of Vigadexa in Treating Inflammation and Infection Post-cataract Surgery
An Evaluation of the Prophylactic Efficacy and Safety of the Administration of the Combination Formulation of Moxifloxacin 0.5% and Dexamethasone 0.1% Eye Drops in Inflammation and Infection Post-cataract Surgery
- Sponsor
- Alcon Research (Industry)
- Enrolment
- 64 enrolled
- Conditions
- Cataract
- Interventions
- Vigadexa (moxifloxacin 0.5% and dexamethasone 0.1%) eye drops
- Ages
- adults, older adults
- Registry
- NCT00870103
Full record on ClinicalTrials.gov
From the registry
To demonstrate that the combination formulation of Moxifloxacin/Dexamethasone Eye Drop is effective and safe for the prevention of postoperative inflammation as a consequence of cataract extraction surgery.
Primary outcomes
- The Percentage of Patients With a Score of Zero for Anterior Chamber Cells.
- The Percentage of Patients With no Ocular Pain
History
Last registry update
Results first posted
Registered
Primary completion
Started